Bone fracture risk factors in prevalent hemodialysis patients
- 5 September 2019
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 38 (2) , 205-212
Abstract
Bone fractures are an important cause of morbidity and mortality in hemodialysis (HD) patients. The aim of this study was to quantify the incidence of fractures in a cohort of prevalent HD patients and evaluate its relationship with possible risk factors. We performed a retrospective analysis of 341 patients, since they started HD (median of 51 months). Demographic, clinical, and biochemical parameters as well as vascular calcifications (VC) were evaluated. Fifty-seven episodes of fracture were identified with a median HD vintage of 47 months (incidence rate of 31 per 1000 person-years). Age (p < 0.001), female gender (p < 0.001), lower albumin (p = 0.02), and higher VC score (p < 0.001) were independently associated with increased risk of fracture, while active vitamin D therapy (p = 0.03) was associated with decreased risk. A significantly higher risk of incident fracture was also associated with higher values of bone-specific alkaline phosphatase (bALP) (p = 0.01) and intact parathyroid hormone (iPTH) levels either < 300 pg/mL (p = 0.02) or > 800 pg/mL (p < 0.001) compared with 300–800 pg/mL. In conclusion, bone fracture incidence in HD patients is high and its risk increases with age, female gender, lower serum albumin, and with the presence of more VC. Prevalent HD patients with low or high iPTH levels or increased bALP also had a higher fracture risk. Therapy with active vitamin D seems to have a protective role. Assessment of fracture risk and management in dialysis patients at greatest risk requires further study.Keywords
This publication has 40 references indexed in Scilit:
- A Pooled Analysis of Vitamin D Dose Requirements for Fracture PreventionNew England Journal of Medicine, 2012
- Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patientsHemodialysis International, 2010
- Low Bone Volume—A Risk Factor for Coronary Calcifications in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft TissueClinical Journal of the American Society of Nephrology, 2009
- High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and deathKidney International, 2008
- Vitamin D levels, bone turnover and bone mineral density show seasonal variation in patients with chronic kidney disease stage 5Nephrology, 2007
- Paricalcitol [19-Nor-1,25-(OH)2D2] in the Treatment of Experimental Renal Bone DiseaseJournal of Bone and Mineral Research, 2006
- Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failureNephrology Dialysis Transplantation, 2004
- Risk Factors for Hip Fracture in Hemodialysis PatientsAmerican Journal of Nephrology, 2002
- Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoformsKidney International, 2001